Assenagon Asset Management
BOLT icon

Assenagon Asset Management’s Bolt Biotherapeutics BOLT Stock Holding History

Assenagon Asset Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,039
Closed -$11.1K – 1180
2024
Q4 		$11.1K Hold
1,039
– – ﹤0.01% 1305
2024
Q3 		$13.5K Sell
1,039
-685
-40% -$9.44K ﹤0.01% 1357
2024
Q2 		$25.9K Buy
+1,724
New +$34K ﹤0.01% 1400
2023
Q3 		– Sell
-7,914
Closed -$203K – 1388
2023
Q2 		$203K Sell
7,914
-3,377
-30% -$107K ﹤0.01% 1284
2023
Q1 		$314K Hold
11,291
– – ﹤0.01% 1290
2022
Q4 		$294K Sell
11,291
-2,708
-19% -$74.2K ﹤0.01% 1245
2022
Q3 		$414K Buy
13,999
+221
+2% +$9.14K ﹤0.01% 1135
2022
Q2 		$562K Buy
+13,778
New +$535K ﹤0.01% 1204

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management's BOLT Position: Q1 2025 in Review

Assenagon Asset Management sold out of Bolt Biotherapeutics (BOLT) in Q1 2025, closing a stake of 1,039 shares — an estimated $11.1K sold.

Assenagon Asset Management first reported a position in BOLT in Q2 2022 and held it in 8 quarters. The position peaked at $562K in Q2 2022. 29 funds tracked by Wall St. Rank hold BOLT as of Q1 2025.

  • Assenagon Asset Management reported no remaining Bolt Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 1,039 Bolt Biotherapeutics shares in Q1 2025, an estimated $11.1K.
  • Assenagon Asset Management first reported a position in Bolt Biotherapeutics in Q2 2022 and held it in 8 quarters.
  • Assenagon Asset Management's Bolt Biotherapeutics position peaked at $562K in Q2 2022.
  • 29 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2025.

Based on Assenagon Asset Management's 13F filing for Q1 2025, filed 15 Apr 2025.